Next Article in Journal
Chrysanthemum Stunt Viroid Resistance in Chrysanthemum
Next Article in Special Issue
Development of Small-Molecule MERS-CoV Inhibitors
Previous Article in Journal
Strawberry Vein Banding Virus P6 Protein Is a Translation Trans-Activator and Its Activity Can be Suppressed by FveIF3g
Previous Article in Special Issue
Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
Open AccessArticle

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice

1
Institute for Infectious Diseases and Zoonoses, LMU Munich, 80539 Munich, Germany
2
German Center for Infection Research (DZIF), partner site Munich, 80539 Munich, Germany
*
Author to whom correspondence should be addressed.
Viruses 2018, 10(12), 718; https://doi.org/10.3390/v10120718
Received: 22 November 2018 / Revised: 9 December 2018 / Accepted: 14 December 2018 / Published: 16 December 2018
(This article belongs to the Special Issue MERS-CoV)
Middle East respiratory syndrome coronavirus (MERS-CoV), a novel infectious agent causing severe respiratory disease and death in humans, was first described in 2012. Antibodies directed against the MERS-CoV spike (S) protein are thought to play a major role in controlling MERS-CoV infection and in mediating vaccine-induced protective immunity. In contrast, relatively little is known about the role of T cell responses and the antigenic targets of MERS-CoV that are recognized by CD8+ T cells. In this study, the highly conserved MERS-CoV nucleocapsid (N) protein served as a target immunogen to elicit MERS-CoV-specific cellular immune responses. Modified Vaccinia virus Ankara (MVA), a safety-tested strain of vaccinia virus for preclinical and clinical vaccine research, was used for generating MVA-MERS-N expressing recombinant N protein. Overlapping peptides spanning the whole MERS-CoV N polypeptide were used to identify major histocompatibility complex class I/II-restricted T cell responses in BALB/c mice immunized with MVA-MERS-N. We have identified a H2-d restricted decamer peptide epitope in the MERS-N protein with CD8+ T cell antigenicity. The identification of this epitope, and the availability of the MVA-MERS-N candidate vaccine, will help to evaluate MERS-N-specific immune responses and the potential immune correlates of vaccine-mediated protection in the appropriate murine models of MERS-CoV infection. View Full-Text
Keywords: MERS-CoV; MERS-CoV nucleocapsid protein; murine CD8+ T cell epitope; MVA vaccine MERS-CoV; MERS-CoV nucleocapsid protein; murine CD8+ T cell epitope; MVA vaccine
Show Figures

Figure 1

MDPI and ACS Style

Veit, S.; Jany, S.; Fux, R.; Sutter, G.; Volz, A. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice. Viruses 2018, 10, 718. https://doi.org/10.3390/v10120718

AMA Style

Veit S, Jany S, Fux R, Sutter G, Volz A. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice. Viruses. 2018; 10(12):718. https://doi.org/10.3390/v10120718

Chicago/Turabian Style

Veit, Svenja; Jany, Sylvia; Fux, Robert; Sutter, Gerd; Volz, Asisa. 2018. "CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice" Viruses 10, no. 12: 718. https://doi.org/10.3390/v10120718

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop